The HD21 study adds to the body of evidence supporting ADCETRIS as a backbone agent in the treatment of specific lymphomas
Facility in The Woodlands, Texas to produce critical starting material for cell and gene therapy, DNA/RNA-based, and recombinant protein therapeutics in Q1/2025
Partnership to facilitate collaborative research in academia and industry to further progress in life sciences
Strategic focus on India aims to make the Swoop® portable MR brain imaging system commercially available in a vast and underserved MRI market
Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history
The acquisition is immediately accretive and creates a compelling, single-stop, multi-continent partner for biopharma companies
Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs
The collaboration aims to bolster healthcare entrepreneurship
Subscribe To Our Newsletter & Stay Updated